Published in final edited form as:

Psychiatr Serv. 2009 April ; 60(4): 520–527. doi:10.1176/ps.2009.60.4.520.

Effects of Prior Authorization on Medication Discontinuation Among Medicaid Beneficiaries With Bipolar Disorder

Yuting Zhang, Ph.D., Alyce S. Adams, Ph.D., Dennis Ross-Degnan, Sc.D., Fang Zhang, Ph.D., and Stephen B. Soumerai, Sc.D.

During the conduct of this study, Dr. Y. Zhang was a research fellow at the Drug Policy Research Group at Harvard Medical School, Boston; she is now with the Department of Health Policy and Management, University of Pittsburgh. Dr. Adams, Dr. Ross-Degnan, and Dr. F. Zhang are affiliated with the Department of Ambulatory Care and Prevention, Harvard Medical School, and with Harvard Pilgrim Health Care, Boston.

Abstract

Objective: Few data exist on the cost and quality effects of increased use of prior-authorization policies to control psychoactive drug spending among persons with serious mental illness. This study examined the impact of a prior-authorization policy in Maine on second-generation antipsychotic and anticonvulsant utilization, discontinuations in therapy, and pharmacy costs among Medicaid beneficiaries with bipolar disorder.

Methods: Using Medicaid and Medicare utilization data for 2001–2004, the authors identified 5,336 patients with bipolar disorder in Maine (study state) and 1,376 in New Hampshire (comparison state). With an interrupted time-series and comparison group design, longitudinal changes were measured in second-generation antipsychotic and anticonvulsant use; survival analysis was used to examine treatment discontinuations and rates of switching medications.

Results: The prior-authorization policy resulted in an 8–percentage point reduction in the prevalence of use of nonpreferred second-generation antipsychotic and anticonvulsant medications (those requiring prior authorization) but did not increase use of preferred agents (no prior authorization) or rates of switching. The prior-authorization policy reduced total pharmacy reimbursements for bipolar disorder by \$27 per patient during the eight-month policy period. However, the hazard rate of treatment discontinuation (all bipolar drugs) while the policy was in effect was 2.28 (95% confidence interval=1.36–4.33) higher than during the prepolicy period, with adjustment for trends in the comparison state.

Conclusions: The small reduction in pharmacy spending for bipolar treatment after the policy was implemented may have resulted from higher rates of medication discontinuation rather than switching. The findings indicate that the prior-authorization policy in Maine may have increased patient risk without appreciable cost savings to the state.

Because of recent rapid inflation in expenditures for prescription drugs, especially psychoactive medications, state Medicaid programs have increasingly relied on prior

authorization to control Medicaid drug spending. A 2005 survey of 36 states and the District of Columbia found that all had attempted to control Medicaid drug costs by requiring prior authorization for some medications and that more than one-third of Medicaid programs and Medicare Part D plans required prior authorization for one or more second-generation antipsychotic medications (1–4). A prior-authorization program requires physicians to obtain special approval before they can prescribe restricted (nonpreferred) medications. Prior-authorization policies have been shown to be very effective at reducing pharmacy expenditures while not increasing adverse outcomes when applied to drug classes in which drugs are highly substitutable and more expensive drugs are not necessarily more effective (5–7). However, the economic and clinical effects of prior-authorization policies for essential psychiatric medications are poorly understood, especially for vulnerable, low-income beneficiaries with bipolar disorder.

Bipolar disorder affects 2.6% of the American general population age 18 and older in any given year and costs \$45 billion per year (including direct medical costs and indirect economic costs) in the United States (8,9). Primary treatment for bipolar disorder includes traditional mood stabilizers, second-generation antipsychotics, and anticonvulsant agents. Drug therapy for bipolar disorder is effective in controlling both manic and depressive episodes and in preventing relapses, hospital admissions, and institutionalization (10,11). Patients who prematurely discontinue treatment have higher costs because of increased rates of functional impairment, rehospitalization, full episode recurrences, and suicide (12). Response to drug therapy may differ, depending on the severity of an episode; presence of comorbid psychiatric disorders, such as substance abuse, anxiety disorders, or attention-deficit hyperactivity disorder; presence of general medical conditions, such as kidney insufficiency; demographic factors, including family supports; and personal history of response to a particular agent (13).

In July 2003 the Maine Medicaid program instituted a prior-authorization policy affecting new prescriptions for nonpreferred agents used to treat bipolar disorder. This policy affected only initial prescriptions and not refills. Two second-generation antipsychotics, olanzapine and aripiprazole, were designated as nonpreferred drugs that required prior authorization before dispensing. In addition, for this drug class only, physicians could prescribe subsequent preferred agents—ziprasidone and quetiapine—after failure of an initial preferred agent (risperidone). Among anticonvulsants, lamotrigine, topiramate, gabapentin, brand-name carbamazepine, brand-name valproic acid, oxcarbazepine, and levetiracetam were listed as nonpreferred. The prior-authorization requirement for second-generation antipsychotics was discontinued in March 2004, eight months after policy implementation, although the requirement remains in effect for newer anticonvulsants. The Maine prior-authorization policy permitted physicians to prescribe nonpreferred medications only after failure of a preferred agent used at full therapeutic dosages for at least two weeks or after submitting a form requesting prior authorization by documenting (with supporting office notes) medical necessity for the nonpreferred medication.

The prior-authorization policy in Maine for new antipsychotic and anticonvulsant medications may have changed treatment patterns among patients newly treated for bipolar disorder. First, to avoid the hassle of the prior-authorization process, physicians may have

been more likely to prescribe the preferred agents, resulting in a population-level shift in treatment toward preferred agents. However, in a previous study of patients with schizophrenia, we found that the Maine policy was also associated with higher risk of therapy discontinuity (specifically, gaps in use and switching medications) (14). We hypothesized that the policy may have led to higher rates of treatment discontinuity if administrative problems created unintended barriers to refilling medications or if patients taking preferred medications experienced side effects or other undesirable outcomes.

In this study we conducted an evaluation with a strong quasi-experimental design of the real-world effects of prior authorization on market share, treatment discontinuation, and spending for second-generation antipsychotic and anticonvulsant agents for patients with bipolar illness. On the basis of the results of our previous study, we hypothesized that the policy would result in a shift toward prescribing newer agents and increased rates of disruptions in therapy among patients newly treated during the policy period.

Methods

Medicaid and Medicare data

Using data from a previous study of schizophrenia, we analyzed complete Medicaid claims extracted from the Medicaid Statistical Information System for 2001–2004 for Maine (the study state) and New Hampshire (comparison state) (14). If patients were concurrently enrolled in Medicare, we obtained their Medicare claims and enrollment data and linked them to Medicaid claims via a unique patient identifier used in both systems (14). For all patients, Medicaid was the primary source of pharmacy claims data. Pharmacy claims contained patient-identifying information, the National Drug Code, the prescription-filled date, the number of units provided (number of tablets, for example), days' supply, and amount reimbursed.

The Harvard Pilgrim Health Care Institutional Review Board approved the study, waiving consent because our study was conducted with deidentified patient data from a large administrative claims data set.

Study cohorts

Continuously enrolled cohorts.—We identified patients who were continuously enrolled in Maine or New Hampshire Medicaid during the study period (January 2001 to December 2004), who were age 18 or older in 2001, and who had at least one inpatient or two outpatient diagnoses of bipolar disorder (*ICD-9-CM* codes 296.0, 296.1, 296.4–296.7, 296.89, and 301.11) during the study period (14). There were 6,712 patients (5,336 in Maine and 1,376 in New Hampshire) in the continuously enrolled cohorts.

Newly treated cohorts.—The prior-authorization policy implemented in Maine Medicaid on July 1, 2003, was intended to affect new prescriptions of nonpreferred drugs. We therefore identified all patients who were newly treated with any bipolar medications. As in our previous study, we required newly treated patients to have had no use of bipolar medications in the 90 days before the initial prescription was filled (14). To examine the policy impact, we identified two cohorts of newly treated patients in each state. We defined

the “policy cohort” as patients who initiated any bipolar medication between July 1, 2003, and February 29, 2004 (Maine, 946 patients; New Hampshire, 133 patients). We defined the “prepolicy cohort” as those who initiated bipolar medication between July 1, 2002, and February 28, 2003, the same calendar period one year before implementation of the policy (Maine, 1,014 patients; New Hampshire, 133 patients). A small proportion of beneficiaries were in both the prepolicy and policy cohorts (60, or 6% in Maine and seven, or 5% in New Hampshire).

We defined the index date as the date of the first prescription filled.

We required newly treated patients to be continuously enrolled for eight months before and eight months after the index date. They also were required to meet the same age and diagnostic criteria as the continuously enrolled cohort.

Outcome measures

Bipolar drug utilization and expenditures.—For the continuously enrolled cohort, we created measures of prevalence of medication use and cost. Prevalence of use of nonpreferred and preferred medications per month was defined by distributing filled prescriptions over time according to their days’ supply and then calculating the proportion of patients who had any bipolar drug use in each month.

To determine changes in Medicaid pharmacy spending for bipolar treatments, we used previously validated methods to calculate the average pharmacy reimbursements per person per month (14).

Prior authorization and discontinuation of bipolar medication.

We defined discontinuation as having a gap in use of any bipolar medication of at least 30 days, measured from the time the days’ supply from all prior prescriptions filled had been allocated until the time of the subsequent prescription (14). The day of discontinuation was defined as the day after the last day of treatment availability (preceding the gap of 30 or more days). Shorter times until discontinuation would suggest an increased rate of disruption in treatment.

Switching and augmentation of the initial drug regimen.

We identified patients who initiated only one drug (rather than multiple drugs) in a specific therapeutic category affected by prior authorization. Switching was defined as a change from the initial drug regimen. Augmentation was defined as filling prescriptions for additional medications used for bipolar illness (lithium and second-generation antipsychotic and anticonvulsant agents) after the initiation of bipolar drug therapy.

Statistical analysis

We used segmented time-series regression models to examine the impact of the prior-authorization policy on the prevalence of use of preferred versus nonpreferred bipolar medications and their associated costs in the continuously enrolled cohort. The prior-authorization policy for second-generation antipsychotic agents was implemented for only

eight months. To demonstrate the policy impact, we created three eight-month segments: the prepolicy period (November 1, 2002, through June 30, 2003), the policy period (July 1, 2003, through February 29, 2004), and the postpolicy period (March 1, 2004, through October 31, 2004). We used the same three segments to estimate the impact of prior authorization on the use of anticonvulsants as well, but during the last period (March 1, 2004, through October 31, 2004) a prior-authorization policy was still in effect for anticonvulsants. This difference allowed us to compare the effects of prior authorization for second-generation antipsychotics and anticonvulsants. The time-series models estimated changes in levels and monthly trends of medication use and expenditures for each segment and for both study and comparison groups. In the time-series regression, we controlled for all significant autocorrelation terms and excluded nonsignificant ($p > .10$) time-series terms step by step (15).

We used extended Cox regression models to examine the impact of the prior-authorization policy on hazard rates of treatment discontinuation and medication switching or augmentation in the newly treated prepolicy and policy cohorts. We calculated the relative ratios of hazard rates between the policy and prepolicy cohorts of newly treated patients in Maine and compared them with the relative ratios in New Hampshire. In the extended Cox hazards model, we included indicators for policy, state, and the policy-state interaction term (a “difference-in-difference” estimate). We controlled for age, gender, and dual enrollment in Medicaid and Medicare. We also controlled for two comorbidity measures: the number of nonbipolar medications dispensed and the number of inpatient admissions (16).

In the outpatient setting, medications are often prescribed on a monthly basis. We used days’ supply indicated on the claims as a proxy for actual drug utilization. Because patients typically receive a 30-day supply of medications, we could not identify the exact date of discontinuation within a 30-day period. For example, even if a patient stopped taking medicines one week after the initiation of therapy, she or he would be categorized as having discontinued on day 31 after initiation of therapy, rather than on day 8. As a result, there was a cluster of discontinuations at 30 days’ postinitiation of therapy. To address this limitation, we allowed the baseline hazard rates of discontinuation for those who discontinued drug therapy more than 30 days after initiation of therapy to differ from the baseline hazard rates of those who discontinued at 30 or fewer days. This adjustment was made by using an extended Cox hazard model, in which we stratified patients according to the timing of discontinuation (≤ 30 days versus >30 days).

Results

Background characteristics of study cohorts

Most demographic and utilization characteristics of enrollees were comparable during the baseline period between Maine and New Hampshire (Table 1). In both states, continuously enrolled patients were more likely to be female than male (67% in Maine and 69% in New Hampshire), 51% were between the ages of 35 and 54, about 38% had used a preferred second-generation antipsychotic, 57% used an anticonvulsant agent, and the lifetime rate of hospitalization was about 32%. However, Maine patients were younger than New Hampshire patients (33% aged 18–34 in Maine, compared with 19% in New Hampshire), and a greater

proportion of patients in New Hampshire were dually enrolled in Medicaid and Medicare. Half of the Maine patients used a second-generation antipsychotic agent, compared with 60% in New Hampshire. Seventeen percent of Maine patients used solely lithium at baseline, compared with 23% of New Hampshire patients. Combinations of drug treatment were common (Table 1).

For newly treated patients, baseline drug utilization patterns were similar between the study and comparison groups. Sixty-five percent of Maine patients were female, compared with 77% of New Hampshire patients. Slightly more than 40% of patients in both states were aged 35 to 54. At baseline, 34% of Maine patients had ever been hospitalized, compared with 40% of New Hampshire patients.

Effects of prior authorization on use of medications

Before the implementation of the prior-authorization policy, the prevalence of use of all nonpreferred medications (specifically, second-generation antipsychotics and anticonvulsants that later required prior authorization) among four-year continuous enrollees was 30% in Maine, with a small upward trend of .05% per month, and 34% in New Hampshire with a similar upward trend (Figure 1, top). During the eight-month policy period (July 2003–February 2004), the upward trend in the use of nonpreferred medications reversed in Maine, yet the upward trend remained unchanged in New Hampshire. When we used the trend before the prior-authorization period as a counterfactual and controlled for secular trends suggested by the comparison state, the prior-authorization policy was associated with an 8-point decrease in the prevalence of use of nonpreferred bipolar drugs over the eight-month policy period. After the prior-authorization policy ended for second-generation antipsychotic agents, the downward trend in the prevalence of use of nonpreferred second-generation antipsychotics stopped, and the prevalence of use remained stable during the postpolicy period (March 2004–October 2004) (Figure 1, middle). However, the downward trend in use of nonpreferred anticonvulsants persisted (Figure 1, bottom).

The prevalence of use of preferred medications was stable at 41% in Maine and 55% in New Hampshire before the policy intervention. During the eight-month policy period, the prevalence of use of preferred drugs increased by 1% in both states. After the policy was repealed, we observed a slight decrease in use of preferred drugs in Maine of 1% during eight months, whereas use of preferred drugs in New Hampshire remained stable.

Pharmacy spending by Medicaid for bipolar medications

The average monthly costs (adjusted for changes in the consumer price index for health care) of all bipolar medications in Maine was about \$167 per patient per month in November 2002, with a monthly increase in trend of \$3.60 per patient per month during the eight months before the prior-authorization policy went into effect (Figure 2). In New Hampshire during the same period, the average monthly spending for all bipolar medications was about \$232, with a slower monthly increase in trend of \$2.80 per patient per month. After the prior-authorization policy was implemented in Maine, the trend leveled off, and in New Hampshire the upward trend continued during the policy period. The prior-authorization

policy was associated with a downward trend in pharmacy costs of \$3.40 per patient per month. Thus the estimated overall medication savings during the eight-month policy period was about \$27 per patient. For 5,336 continuously enrolled patients in Maine, the total savings in drug spending was \$144,072. When the prior-authorization policy ended February 29, 2004, the spending trend in Maine was similar to that seen in New Hampshire during the same period.

Changes in rates of bipolar drug treatment discontinuations

We used Kaplan-Meier survival curves to compare hazard rates for treatment discontinuations between the prepolicy and policy cohorts in the study and comparison states (Figure 3, top). Compared with the prepolicy period, the policy period was associated with an increase in the proportion of newly treated patients who discontinued therapy. When we controlled for the relative hazard ratios between the prepolicy and policy cohorts in the comparison group, the policy was associated with a 2.28 (95% confidence interval [CI]=1.15–4.52) higher adjusted hazard of discontinuation of all bipolar medications 30 days after therapy initiation, compared with the prepolicy cohort. This effect was not observed for treatment discontinuation within 30 days of initiation (relative hazard rate=.97, 95% CI=.54–1.74). In the policy cohort in Maine, the percentages of patients who discontinued treatment at any given point in follow-up were consistently higher than in the prepolicy cohort, representing an increase in risk. At 30 days after initiation of medication, there was a 5-percentage point absolute increase between policy and prepolicy cohorts in rates of discontinuation in Maine and a 6-percentage point decrease between cohorts in New Hampshire; at 50 days, these differences were a 6-percentage point increase in Maine and a 4-percentage point decrease in New Hampshire; and at 250 days, there was a 10-percentage point increase in Maine and a 6-percentage point decrease in New Hampshire.

Changes in rates of switching and augmentation

There were no differences in hazard rates of switching or augmentation of the initial medication regimen between the policy and prepolicy cohorts observed in both the study and comparison states (Figure 3, bottom). This finding suggests that the prior-authorization policy did not affect the switching or augmentation rates of the initial regimen of bipolar medication.

Discussion

Psychiatric medications account for 15% of total Medicaid drug spending, and expenditures have increased by 150% from 1998 to 2002 (3). State Medicaid programs face increasing pressure to control drug expenditures and to rely on prior-authorization policies. However, few well-controlled studies have examined the economic and clinical impacts of such policies. This study is the first to use a strong quasi-experimental design to examine the impact of requiring prior authorization for bipolar medications among vulnerable Medicaid enrollees. We found that the Maine prior-authorization policy did not affect the use of preferred drugs but decreased the use of nonpreferred drugs and decreased medication costs by \$3.40 per patient with bipolar illness per month during the eight-month policy period. Some of this savings was likely offset by the unmeasured administrative costs of prior

authorization itself, previously estimated at approximately \$20 per prior-authorization request (5,17).

Further, under the prior-authorization policy, Maine patients newly treated with nonpreferred medicines were at greater risk of discontinuation of treatment with any bipolar medication compared with similar patients in New Hampshire; this 2.28 (CI=1.15–4.52) increase in adjusted risk of discontinuation mainly occurred between 30 days and 250 days after the initiation of therapy. The absolute difference in risk was smaller, at 30 days and 50 days after initiation. These results are consistent with our previous analyses of prior-authorization effects among patients with schizophrenia, which showed that the policy cohort in Maine had a 1.29 (CI=1.02–1.63) greater hazard of treatment discontinuity than the prepolicy cohort. However, we found no evidence of an increase in medication switching or augmentation with other medications. Individuals with bipolar disorder each respond to drug therapy differently, and therapy often must be customized according to a patient's individual historical response to specific medications or current response to treatment (18). To the extent that prior authorization creates administrative barriers to tailoring medication management for particular patients, their treatment may be discontinued. Thus the preponderance of savings from the Maine policy may be due to discontinuation of therapy rather than to switching to a preferred agent. Discontinuation of all medication treatment is an undesirable outcome, because bipolar disorder is a chronic illness and premature discontinuation of treatment results in higher rates of relapses, hospitalization, and suicide (12).

These findings were highly consistent with our previous study of patients with schizophrenia, which indicated a need to assess the long-term clinical and economic consequences of the increased use of prior-authorization policies in Medicaid and Medicare for drug classes that are likely to differentially affect persons with severe mental illness (14). More information is needed to assess the clinical impacts of these policies across a range of clinical conditions and population subgroups. Prior-authorization policies may be an effective tool to encourage use of appropriate medications. However, special measures may be required to protect the health of vulnerable groups of patients with mental illness (19). One key principle is to update preferred drug lists to incorporate the most recent clinical evidence on safety, effectiveness, and cost-effectiveness of medications. For example, the Agency for Healthcare Research and Quality's Developing Evidence to Inform Decisions About Effectiveness (DE-cIDE) network may provide comparative effectiveness data to inform drug policy decisions (20).

There are a few limitations of our study. First, we did not assess the policy's impact on use of medical care. In addition, we could not measure whether patients in either state obtained care in the other state's Medicaid program. Our estimates of changes in drug expenditures postpolicy did not include potential increases in rebates offered to the state Medicaid program by companies whose products were on the preferred list.

Conclusions

Our findings suggest that prior-authorization policies, although reasonable in their purpose to reduce pharmacy spending, might still lead to unintended and unexpected consequences, especially for patients with chronic mental illness. The goal of the Maine prior-authorization program was to direct initial treatment choice toward less expensive medications. If the initial preferred medication did not work well, patients could be switched to second-line treatment. However, rather than resulting in an increase in medication switching, the strongest policy impact was discontinuation of all medication treatment. Until the broad economic and clinical impacts of prior-authorization policies targeting essential psychiatric medications are better known, these policies should be used with caution among vulnerable patients with chronic mental illness.

Acknowledgments and disclosures

This study was mainly funded by grant 63213 from the Robert Wood Johnson Foundation's changes in health care financing and organization initiative. Dr. Y. Zhang acknowledges funding from a Thomas O. Pyle fellowship and a fellowship in pharmaceutical policy at the Department of Ambulatory Care and Prevention, Harvard Medical School (where this work was conducted). Support was also provided by the HMO Research Network Center for Education and Research in Therapeutics (CERT), funded by the Agency for Healthcare Research and Quality (AHRQ).

With the exception of Dr. Y. Zhang, who reports no competing interests, the authors report conducting a previous study of prior authorization of medications for schizophrenia that was supported by a public-private partnership program of AHRQ, CERT, and the HMO Research Network CERT; Eli Lilly and Company; the Centers for Disease Control and Prevention; and the Harvard Pilgrim Health Care Foundation.

References

1. Huskamp H, Stevenson D, Donohue J, et al.: Coverage and prior authorization of psychotropic drugs under Medicare Part D. *Psychiatric Services* 58:308–310, 2007 [PubMed: 17325102]
2. Koyanagi C, Forquer S, Alfano E: Medicaid policies to contain psychiatric drug costs. *Health Affairs* 24:536–544, 2005 [PubMed: 15757941]
3. Polinski JM, Wang PS, Fischer MA: Medicaid's prior authorization program and access to atypical antipsychotic medications. *Health Affairs* 26:750–760, 2007 [PubMed: 17485754]
4. Kaiser Commission on Medicaid and the Uninsured: State Medicaid Outpatient Prescription Drug Policies: Findings From a National Survey, 2005 Update. Pub no 7381. Washington, DC, Kaiser Family Foundation, 2005 Available at www.kff.org/medicaid/7381.cfm
5. Delate T, Mager DE, Sheth J, et al.: Clinical and financial outcomes associated with a proton pump inhibitor prior-authorization in a Medicaid population. *American Journal of Managed Care* 11:29–36, 2005 [PubMed: 15697098]
6. Fischer MA, Choudhry NK, Winkelmayer WC: Impact of Medicaid prior authorization on angiotensin-receptor blockers: can policy promote rational prescribing? *Health Affairs* 26:800–807, 2007 [PubMed: 17485759]
7. Yokoyama K, Yang W, Preblich R, et al.: Effects of a step-therapy program for angiotensin receptor blockers on antihypertensive medication utilization patterns and cost of drug therapy. *Journal of Managed Care Pharmacy* 13:235–244, 2007 [PubMed: 17407390]
8. Kessler RC, Chiu WT, Demler O, et al.: Prevalence, severity, and comorbidity of twelve-month DSM-IV disorders in the National Comorbidity Survey Replication (NCS-R). *Archives of General Psychiatry* 62:617–627, 2005 [PubMed: 15939839]
9. Sajatovic M: Bipolar disorder: disease burden. *American Journal of Managed Care* 11:S80–S84, 2005 [PubMed: 16097718]

10. Bauer M: Review: lithium reduces relapse rates in people with bipolar disorder. *Evidence-Based Mental Health* 7:72–73, 2004 [PubMed: 15273216]
11. Tohen M, Greil W, Calabrese JR, et al.: Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. *American Journal of Psychiatry* 162:1281–1290, 2005 [PubMed: 15994710]
12. Bowden CL, Krishnan AA: Pharmacotherapy for bipolar depression: an economic assessment. *Expert Opinion on Pharmacotherapy* 5:1101–1107, 2004 [PubMed: 15155111]
13. Gelenberg AJ, Pies R: Matching the bipolar patient and the mood stabilizer. *Annals of Clinical Psychiatry* 15:203–216, 2003 [PubMed: 14971866]
14. Soumerai SB, Zhang F, Ross-Degnan D, et al.: Use of atypical antipsychotic drugs for schizophrenia in Maine Medicaid following a policy change. *Health Affairs* 27:w185–w195, 2008 [PubMed: 18381404]
15. Wagner AK, Soumerai SB, Zhang F: Segmented regression analysis of interrupted time series studies in medication use research. *Journal of Clinical Pharmacy and Therapeutics* 27:299–309, 2002 [PubMed: 12174032]
16. Schneeweiss S, Seeger JD, Maclure M, et al.: Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. *American Journal of Epidemiology* 154:854–864, 2001 [PubMed: 11682368]
17. Motheral BR, Henderson R, Cox ER: Plansponsor savings and member experience with point-of-service prescription step therapy. *American Journal of Managed Care* 10:457–464, 2004 [PubMed: 15298367]
18. Practice guideline for the treatment of patients with bipolar disorder (revision). *American Journal of Psychiatry* 159(Apr suppl):1–50, 2002
19. Zeber JE, Grazier KL, Valenstein M, et al.: Effect of a medication copayment increase in veterans with schizophrenia. *American Journal of Managed Care* 13:335–346, 2007 [PubMed: 17567234]
20. DEcIDE Network. Rockville, Md, Agency for Health Care Research and Quality Available at effectivehealthcare.ahrq.gov/aboutUs.cfm?abouttype=decidecert

Figure 1.

Prevalence of use of nonpreferred bipolar medications before, during, and after a prior-authorization policy^a Cohorts were continuously enrolled in Medicare, Medicaid, or both. Fitted trend lines show predicted values estimated from segmented time-series regressions for the Maine study (N=5,336) and New Hampshire comparison (N=1,376) groups. The last two observation periods (September and October) for New Hampshire were omitted because they occurred after the state started its own prior-authorization policy in September 2004.

Figure 2. Medicaid expenditures for bipolar medications among continuously enrolled patients in Maine (N=5,336) and New Hampshire (N=1,376)^a Fitted trend lines show predicted values estimated from segmented time-series regressions. New Hampshire started its own prior-authorization policy in September 2004.

Figure 3.

Time to treatment discontinuation and switching or augmentation of initial drug therapy among newly treated patients before and during implementation of a prior-authorization policy^a Discontinuation was defined as 30 days without any study drug therapy after the initial medication regimen. The prepolicy observation period was July 2002 through February 2003; the policy observation period was July 2003 through February 2004.

Baseline characteristics of the study and comparison cohorts of Medicare and Medicaid beneficiaries with bipolar disorder^a

Table 1

Characteristic	Continuously enrolled ^b			Newly treated ^c		
	Study (Maine) (N=5,336)	Comparison (New Hampshire) (N=1,376)		Study (Maine) (N=1,960)	Comparison (New Hampshire) (N=266)	
	N	%	N	%	N	%
Female ^d	3,580	67	944	69	205	77
Age in January 2001						
18–34 ^e	1,761	33	261	19	120	45
35–54 ^d	2,737	51	695	51	109	41
55–63 ^e	843	16	427	31	40	15
Race: white	5,203	98	1,339	97	257	97
Dually enrolled in Medicare and Medicaid ^f	2,791	52	949	69	104	39
Bipolar medications used ^g						
Lithium only ^f	928	17	316	23	18	7
2nd-generation antipsychotic ^f	2,657	50	826	60	49	18
Nonpreferred ^f	1,030	19	399	29	16	6
Preferred	2,006	38	537	39	35	13
Anticonvulsant	3,020	57	779	57	65	24
Carbamazepine	466	9	134	10	8	3
Valproic acid ^e	1,249	23	440	32	27	10
Nonpreferred ^f	1,916	36	372	27	33	12
Lithium with 2nd-generation antipsychotic ^f	539	10	206	15	5	2
Lithium with anticonvulsant ^f	448	8	138	10	5	2
2nd-generation antipsychotic with anticonvulsant	1,809	34	495	36	22	8

Characteristic	Continuously enrolled ^b			Newly treated ^c		
	Study (Maine) (N=5,336)		Comparison (New Hampshire) (N=1,376)	Study (Maine) (N=1,960)		Comparison (New Hampshire) (N=266)
	N	%	N	%	N	%
Co-occurring psychiatric diagnoses ^h						
Bipolar II ^e	683	13	110	8	326	17
Schizophrenia ^f	1,153	22	358	26	202	10
Depression ^e	2,711	51	578	42	1,070	54
Number of unique medications per patient (M±SD) ^e	9.2±5.9		11.3±7.0		6.6±4.8	8.3±5.9
Ever hospitalized ^d	1,692	32	454	33	666	34
					106	40

^aThe baseline period is 2002 for continuously enrolled beneficiaries and eight months before initiation of the index drug for the newly treated cohort. All values are based on nonmissing data.

^bContinuously enrolled in Medicaid from January 1, 2001, to January 12, 2004, with one inpatient or two outpatient diagnoses of bipolar disorder during that period and age 18 or older in 2001

^cInitiated nonpreferred second-generation antipsychotic or anticonvulsant medication, with no use in the previous 90 days. Patients with 45 or more days' stay in an institutional setting during that period were excluded. Patients without at least one inpatient or two outpatient diagnoses of bipolar disorder during the eight months before and after initiation of a second-generation antipsychotic were also excluded.

^dp<.05 between states for newly treated groups

^ep<.05 between states for newly treated and continuously enrolled groups

^fp<.05 between states for continuously enrolled groups

^gPercentages in newly treated cohort represent use during a five-month period because patients were required to have no use of bipolar medication in the 90 days before initiation; thus prevalence of use for the continuously enrolled is not comparable with that for the newly treated cohorts.

^hDiagnoses were as defined by ICD-9: schizophrenia, code 295; depression, codes 296.2, 296.3, and 311; and bipolar disorder II, codes 296.0, 296.1, 296.4–296.7, 296.89, and 301.11.